Mirtazapine
- Generic Name
- Mirtazapine
- Brand Names
- Remeron
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3
- CAS Number
- 85650-52-8
- Unique Ingredient Identifier
- A051Q2099Q
- Background
Mirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder. The effects of this drug may be observed as early ...
- Indication
This drug is indicated for the treatment of major depressive disorder and its associated symptoms.
...
- Associated Conditions
- Cancer Pain, Depression, Fibromyalgia, Generalized Anxiety Disorder, Hot Flashes, Insomnia, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Persistent Depressive Disorder (Dysthymia), Post Operative Nausea and Vomiting (PONV), Poststroke depression, Sleep disorders and disturbances, Substance Abuse Disorders, Tension Headache
- Associated Therapies
- -
Mirtazapine for Treating Cocaine Dependent Individuals Who Also Suffer From Depression
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 86
- Registration Number
- NCT00249444
- Locations
- 🇺🇸
Research Foundation for Mental Hygiene, Inc., New York, New York, United States
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2005-09-15
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 60
- Registration Number
- NCT00177567
- Locations
- 🇺🇸
University of Pittsubrgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 80
- Registration Number
- NCT00150839
- Locations
- 🇩🇪
Department of Psychiatry and Psychotherapy, University Erlangen-Nuremberg, Erlangen, Bavaria, Germany
New Pharmacological Treatment for Obstructive Sleep Apnea
- Conditions
- First Posted Date
- 2005-04-18
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00108498
- Locations
- 🇺🇸
Malcom Randall VAMC, Gainesville, Florida, United States
Treatment of Adolescent Suicide Attempters (TASA)
- Conditions
- First Posted Date
- 2004-03-26
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 120
- Registration Number
- NCT00080158
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Columbia University at the New York State Psychiatric Institute, New York, New York, United States
🇺🇸New York University Child Study Center, New York, New York, United States
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
- Conditions
- First Posted Date
- 2001-07-23
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 4000
- Registration Number
- NCT00021528
- Locations
- 🇺🇸
Harbor UCLA Family Health Care Center, Harbor City, California, United States
🇺🇸UCLA General Outpatient Psychiatry Clinic, Los Angeles, California, United States
🇺🇸UCLA Internal Medicine Clinic, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.